New Zealand markets open in 7 hours 40 minutes

Rani Therapeutics Holdings, Inc. (RANI)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
7.16+0.01 (+0.14%)
As of 10:19AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 188.07M
Enterprise value 169.63M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)14.62
Enterprise value/revenue N/A
Enterprise value/EBITDA -2.74

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 382.40%
S&P500 52-week change 325.59%
52-week high 38.75
52-week low 31.82
50-day moving average 34.73
200-day moving average 33.47

Share statistics

Avg vol (3-month) 3145.15k
Avg vol (10-day) 3182.11k
Shares outstanding 526.3M
Implied shares outstanding 651.77M
Float 813.7M
% held by insiders 148.88%
% held by institutions 113.20%
Shares short (15 Apr 2024) 41.72M
Short ratio (15 Apr 2024) 415.31
Short % of float (15 Apr 2024) 413.06%
Short % of shares outstanding (15 Apr 2024) 46.52%
Shares short (prior month 15 Mar 2024) 41.86M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-53.03%
Return on equity (ttm)-172.96%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -62.73M
Net income avi to common (ttm)-33.08M
Diluted EPS (ttm)-1.33
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)39.58M
Total cash per share (mrq)1.5
Total debt (mrq)35.41M
Total debt/equity (mrq)243.62%
Current ratio (mrq)3.10
Book value per share (mrq)0.28

Cash flow statement

Operating cash flow (ttm)-48.48M
Levered free cash flow (ttm)-24.09M